Kettle Hill Capital Management LLC Acquires New Holdings in Henry Schein, Inc. $HSIC

Kettle Hill Capital Management LLC bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 213,319 shares of the company’s stock, valued at approximately $14,158,000. Henry Schein comprises approximately 3.2% of Kettle Hill Capital Management LLC’s holdings, making the stock its 14th biggest holding. Kettle Hill Capital Management LLC owned about 0.18% of Henry Schein at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein in the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein during the 2nd quarter worth approximately $27,000. Sentry Investment Management LLC increased its holdings in Henry Schein by 132.1% in the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after purchasing an additional 515 shares during the last quarter. Evelyn Partners Investment Management Services Ltd acquired a new stake in Henry Schein in the 2nd quarter valued at approximately $62,000. Finally, Mather Group LLC. purchased a new stake in Henry Schein in the third quarter valued at approximately $71,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In other news, Director Philip A. Laskawy sold 2,844 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director directly owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. The trade was a 11.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director owned 15,420 shares in the company, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 104,556 shares of company stock worth $8,476,351. 1.14% of the stock is owned by corporate insiders.

Henry Schein Stock Up 0.8%

Shares of NASDAQ HSIC opened at $75.57 on Monday. The stock has a market cap of $8.67 billion, a P/E ratio of 23.11, a PEG ratio of 2.24 and a beta of 0.87. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29. The business’s fifty day simple moving average is $78.21 and its 200-day simple moving average is $72.89.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period last year, the business posted $1.19 earnings per share. Henry Schein’s revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Robert W. Baird set a $100.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Wells Fargo & Company increased their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Morgan Stanley raised their target price on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.